Androgen deprivation therapy before radical prostatectomy is associated with poorer postoperative erectile function outcomes

BJU International

Volumn 110, Issue 1, 2012, Pages 112-116

  Mazzola, Clarisse R ^a   Deveci, Serkan ^a   Heck, Matthias ^a   Mulhall, John P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Androgen; Castration; Erectile function; Hormonotherapy; Penile rehabilitation; Prostate cancer

Indexed keywords

ANASTOMOSIS LEAKAGE; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; COMORBIDITY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; ERECTILE DYSFUNCTION; GLEASON SCORE; HUMAN; INCIDENCE; INTERNATIONAL INDEX OF ERECTILE FUNCTION; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATECTOMY; TREATMENT DURATION;

EID: 84862279674     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10728.x     Document Type: Article

References (30)

1. Nelson CJ, Deveci S, Stasi J, Scardino PT, Mulhall JP. Sexual bother following radical prostatectomyjsm. J Sex Med 2010; 7: 129-35
2. Tal R, Alphs HH, Krebs P, Nelson CJ, Mulhall JP. Erectile function recovery rate after radical prostatectomy: a meta-analysis. J Sex Med 2009; 6: 2538-46
3. Mulhall JP, Secin FP, Guillonneau B. Artery sparing radical prostatectomy-myth or reality? J Urol 2008; 179: 827-31
4. Secin FP, Touijer K, Mulhall J, Guillonneau B. Anatomy and preservation of accessory pudendal arteries in laparoscopic radical prostatectomy. Eur Urol 2007; 51: 1229-35 (Pubitemid 46436288)
5. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev (Online). 2006 4): CD006019
6. Traish A, Kim N. The physiological role of androgens in penile erection: regulation of corpus cavernosum structure and function. J Sex Med 2005; 2: 759-70 (Pubitemid 41727389)
7. Traish AM, Munarriz R, O'Connell L et al. Effects of medical or surgical castration on erectile function in an animal model. J Androl 2003; 24: 381-7 (Pubitemid 39571794)
8. Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 1999; 140: 1861-8 (Pubitemid 29149259)
9. Traish AM, Guay AT. Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence. J Sex Med 2006; 3: 382-404; discussion -7
10. Foresta C, Caretta N, Rossato M, Garolla A, Ferlin A. Role of androgens in erectile function. J Urol 2004; 171: 2358-62, quiz 435
11. Gray PB, Singh AB, Woodhouse LJ et al. Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men. J Clin Endocrinol Metab 2005; 90: 3838-46 (Pubitemid 41058141)
12. Armagan A, Kim NN, Goldstein I, Traish AM. Dose-response relationship between testosterone and erectile function: evidence for the existence of a critical threshold. J Androl 2006; 27: 517-26 (Pubitemid 44126263)
13. Teloken PE, Ohebshalom M, Mohideen N, Mulhall JP. Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer. J Urol 2007; 178: 2521-5 (Pubitemid 350052155)
14. Mulhall JP, Slovick R, Hotaling J et al. Erectile dysfunction after radical prostatectomy: hemodynamic profiles and their correlation with the recovery of erectile function. J Urol 2002; 167: 1371-5 (Pubitemid 34132096)
15. Ohebshalom M, Parker M, Waters B, Flanagan R, Mulhall JP. Erectile haemodynamic status after radical prostatectomy correlates with erectile functional outcome. BJU Int 2008; 102: 592-6
16. Mullerad M, Donohue JF, Li PS, Scardino PT, Mulhall JP. Functional sequelae of cavernous nerve injury in the rat: is there model dependency. J Sex Med 2006; 3: 77-83
17. Masterson TA, Serio AM, Mulhall JP, Vickers AJ, Eastham JA. Modified technique for neurovascular bundle preservation during radical prostatectomy: association between technique and recovery of erectile function. B JU Int 2008; 1 01: 1217-22 (Pubitemid 351549631)
18. Traish AM, Goldstein I, Kim NN. Testosterone and erectile function: from basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction. Eur Urol 2007; 52: 54-70 (Pubitemid 46803026)
19. Takahashi Y, Hirata Y, Yokoyama S et al. Loss of penile erectile response to intracavernous injection of acetylcholine in castrated dog. T ohoku J Exp Med 1991; 163: 85-91
20. Mulhall JP. The role and structure of a postradical prostatectomy penile rehabilitation program. Curr Urol Rep 2009; 10: 219-25
21. Armagan A, Hatsushi K, Toselli P. The effects of testosterone deficiency on the structural integrity of the penile dorsal nerve in the rat. Int J Impot Res 2008; 20: 73-8
22. Suzuki N, Sato Y, Hisasue S, Kato R, Suzuki K, Tsukamoto T. Effect of testosterone on intracavernous pressure elicited with electrical stimulation of the medial preoptic area and cavernous nerve in male rats. J Androl 2007; 28: 218-22 (Pubitemid 46423902)
23. Mulhall JP. Penile rehabilitation following radical prostatectomy. Curr Opin Urol 2008; 18: 613-20
24. Marumo K, Baba S, Murai M. Erectile function and nocturnal penile tumescence in patients with prostate cancer undergoing luteinizing hormone-releasing hormone agonist therapy. Int J Urol 1999; 6: 19-23 (Pubitemid 30406804)
25. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2008; 179 (Suppl.): S97-S102 (Pubitemid 351483920)
26. Walker LM, Robinson JW. The unique needs of couples experiencing androgen deprivation therapy for prostate cancer. J Sex Marital Ther 2010; 36: 154-65
27. Oefelein MG. Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. J Urol 1998; 160: 1685-8 (Pubitemid 128746738)
28. Pettersson B, Varenhorst E, Petas A, Sandow J. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study. Eur Urol 2006; 50: 483-9 (Pubitemid 44189052)
29. Kaku H, Saika T, Tsushima T et al. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Prostate 2006; 66: 439-44 (Pubitemid 43346954)
30. Wilke DR, Parker C, Andonowski A et al. Testosterone and erectile function recovery after radiotherapy and long-term androgen deprivation with luteinizing hormone-releasing hormone agonists. BJU Int 2006; 97: 963-8